window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : July 30, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Phase 3 schizophrenia trial

  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory

    Newron secures up to EUR 38 million to advance Phase 3 evenamide program in treatment-resistant schizophrenia

    Newron Pharmaceuticals has secured up to EUR 38 million in [...]

    May 5, 2026

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • AI-driven antibody discovery could create $7bn market for life science tools
    Categories: Digital & Data, Drug Delivery & Formulation, Research & Development
  • Pace Life Sciences passes FDA inspection at North Carolina facility
    Categories: Clinical & Regulatory, Manufacturing & Supply Chain
  • CAMP4 wins Australian clearance to begin Phase 1/2 trial of SYNGAP1 therapy
    Categories: Clinical & Regulatory, Pharmaceuticals and therapeutics, Research & Development, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top